The whole-genome landscape of medulloblastoma subtypes
Open accessThe DOI matches its Crossref record; 66 of the 66 references it cites were found in a registry or an index.
Abstract
Current therapies for medulloblastoma, a highly malignant childhood brain tumour, impose debilitating effects on the developing child, and highlight the need for molecularly targeted treatments with reduced toxicity. Previous studies have been unable to identify the full spectrum of driver genes and molecular processes that operate in medulloblastoma subgroups. Here we analyse the somatic landscape across 491 sequenced medulloblastoma samples and the molecular heterogeneity among 1,256 epigenetically analysed cases, and identify subgroup-specific driver alterations that include previously undiscovered actionable targets. Driver mutations were confidently assigned to most patients belonging to Group 3 and Group 4 medulloblastoma subgroups, greatly enhancing previous knowledge. New molecular subtypes were differentially enriched for specific driver events, including hotspot in-frame insertions that target KBTBD4 and ‘enhancer hijacking’ events that activate PRDM6. Thus, the application of integrative genomics to an extensive cohort of clinical samples derived from a single childhood cancer entity revealed a series of cancer genes and biologically relevant subtype diversity that represent attractive therapeutic targets for the treatment of patients with medulloblastoma. Genomic analysis of 491 medulloblastoma samples, including methylation profiling of 1,256 cases, effectively assigns candidate drivers to most tumours across all molecular subgroups. Medulloblastomas are highly malignant brain tumours that develop during childhood. Paul Northcott and colleagues analysed the whole-genome sequences of 491 medulloblastomas in order to characterize the genomic landscape across tumours and identify new drivers and mutational signatures. Their integrative genomic analyses, including methylation profiling of 1,256 medulloblastomas, identifies subgroup-specific driver mutations and suggests additional tumour subtypes. The authors assign driver mutations to a high proportion of the less well characterized Group 3 and Group 4, which together contribute to more than 60% of all medulloblastomas.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures















Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“The overlap observed between the G3 and G4 tumors with respect to MYC amplification supports the working hypothesis that these medulloblastomas are not easily separable in part because they originate from a shared cerebellar progenitor cell pool, with each group arising from arrest at different points along a developmental stage continuum (8, 23).”
From The Medulloblastoma Meta-Analysis Portal Enables Integrative Exploration of Clinical and Genomic Data from Patients (2025) · cites this paper as [8]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Methylation array–based classification studies have categorized the G3/G4-2, G3/G4-3, and G3/G4-4 molecular subgroups as G3; the G3/G4-1, G3/G4-5, and G3/G4-6 subgroups as a mix of G3 and G4; and the G3/G4-7 and G3/G4-8 subgroups as primarily G4 (8).”
From The Medulloblastoma Meta-Analysis Portal Enables Integrative Exploration of Clinical and Genomic Data from Patients (2025) · cites this paper as [8]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Sequence Alignment/Map format and SAMtools
Li, H., Handsaker, B., Wysoker, A., Fennell, T., Ruan, J., Homer, N., Marth, G., Abecasis, G., Durbin, R., & 1000 Genome Project Data Processing Subgroup (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp352 · Cited by 62,041 · cited 2×
“T 0) 42 .”
STAR: ultrafast universal RNA-seq aligner
Dobin, A., Davis, C. A., Schlesinger, F., Drenkow, J., Zaleski, C., Jha, S., Batut, P., Chaisson, M., & Gingeras, T. R. (2013) · Bioinformatics · doi:10.1093/bioinformatics/bts635 · Cited by 51,709
BEDTools: a flexible suite of utilities for comparing genomic features
Quinlan, A. R., & Hall, I. M. (2010) · Bioinformatics · doi:10.1093/bioinformatics/btq033 · Cited by 27,437
The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary
Louis, D. N., Perry, A., Reifenberger, G., von Deimling, A., Figarella-Branger, D., Cavenee, W. K., Ohgaki, H., Wiestler, O. D., Kleihues, P., & Ellison, D. W. (2016) · Acta Neuropathologica · doi:10.1007/s00401-016-1545-1 · Cited by 15,657 · cited 1×
“The relatively recent recognition of consensus MB subgroups has rapidly changed the way MB is studied in the research setting and how it is diagnosed and treated in the clinic 39 .”
The 2007 WHO Classification of Tumours of the Central Nervous System
Louis, D. N., Ohgaki, H., Wiestler, O. D., Cavenee, W. K., Burger, P. C., Jouvet, A., Scheithauer, B. W., & Kleihues, P. (2007) · Acta Neuropathologica · doi:10.1007/s00401-007-0243-4 · Cited by 15,397
ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data
Wang, K., Li, M., & Hakonarson, H. (2010) · Nucleic Acids Research · doi:10.1093/nar/gkq603 · Cited by 14,621 · cited 1×
“The functional effect of the mutations was annotated using Annovar 43 and the variants were assessed for their confidence and split into somatic and non-somatic calls.”
Principal components analysis corrects for stratification in genome-wide association studies
Price, A. L., Patterson, N. J., Plenge, R. M., Weinblatt, M. E., Shadick, N. A., & Reich, D. (2006) · Nature Genetics · doi:10.1038/ng1847 · Cited by 10,248
Signatures of mutational processes in human cancer
Initiative, A. P. C. G., Alexandrov, L. B., ICGC Breast Cancer Consortium, ICGC MMML-Seq Consortium, PedBrain, I., Nik-Zainal, S., Wedge, D. C., Aparicio, S. A. J. R., Behjati, S., Biankin, A. V., et al. (2013) · Nature · doi:10.1038/nature12477 · Cited by 9,660 · cited 1×
“…previously detected in MB 16 and has been linked with underlying BRCA1 and BRCA2 mutations in breast, aggressive prostate, and pancreatic cancers 16,17 , was unexpectedly observed in most of the patients with Group 3 and Group 4 MB, and a subset of patients with SHH MB. Additional…”
Self-citationComprehensive molecular characterization of human colon and rectal cancer
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11252 · Cited by 8,499
dbSNP: the NCBI database of genetic variation
Sherry, S. T. (2001) · Nucleic Acids Research · doi:10.1093/nar/29.1.308 · Cited by 7,502
Cited by
Items 201–300 of 998
Review of molecular classification and treatment implications of pediatric brain tumors
Stücklin, A. G., Ramaswamy, V., Daniels, C., & Taylor, M. D. (2017) · Current Opinion in Pediatrics · doi:10.1097/mop.0000000000000562 · Cited by 53
Self-citationMerk, D. J., Ohli, J., Merk, N. D., Thatikonda, V., Morrissy, A. S., Schoof, M., Schmid, S. N., Harrison, L., Filser, S., Ahlfeld, J., et al. (2018) · Developmental Cell · doi:10.1016/j.devcel.2018.02.012 · Cited by 57
Self-citationKorshunov, A., Sahm, F., Zheludkova, O., Голанов, А. В., Stichel, D., Schrimpf, D., Ryzhova, M. V., Aa, P., Habel, A., Meyer, J., et al. (2018) · Neuro-Oncology · doi:10.1093/neuonc/noy155 · Cited by 50
Self-citationCormerais, Y., Pagnuzzi‐Boncompagni, M., Schrötter, S., Giuliano, S., Tambutté, É., Endou, H., Wempe, M. F., Pagès, G., Pouysségur, J., & Picco, V. (2019) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.14176 · Cited by 52
“The most recent studies combining genetics, epigenetics and RNA expression data have refined and further delineated several sub-groups within these groups [3-6].”
BackgroundIdentification of Targetable Lesions in Anaplastic Thyroid Cancer by Genome Profiling
Ravi, N., Yang, M., Gretarsson, S., Jansson, C., Mylona, N., Sydow, S., Woodward, E. L., Ekblad, L., Wennerberg, J., & Paulsson, K. M. (2019) · Cancers · doi:10.3390/cancers11030402 · Cited by 46
A pediatric brain tumor atlas of genes deregulated by somatic genomic rearrangement
Zhang, Y., Chen, F., Donehower, L. A., Scheurer, M. E., & Creighton, C. J. (2021) · Nature Communications · doi:10.1038/s41467-021-21081-y · Cited by 51
Molecular Stratification of Medulloblastoma: Clinical Outcomes and Therapeutic Interventions
Sursal, T., Ronecker, J. S., Dicpinigaitis, A. J., MOHAN, A. L., Tobias, M. E., Gandhi, C. D., & Jhanwar‐Uniyal, M. (2022) · Anticancer Research · doi:10.21873/anticanres.15703 · Cited by 52
The role of chromatin remodeler SMARCA4/BRG1 in brain cancers: a potential therapeutic target
Navickas, S. M., Giles, K. A., Brettingham‐Moore, K. H., & Taberlay, P. C. (2023) · Oncogene · doi:10.1038/s41388-023-02773-9 · Cited by 53
Colafati, G. S., Voicu, I. P., Carducci, C., Miele, E., Carai, A., Loreto, S. D., Marrazzo, A., Cacchione, A., Cecinati, V., Tornesello, A., et al. (2018) · Therapeutic Advances in Neurological Disorders · doi:10.1177/1756286418775375 · Cited by 45
Pietrobono, S., & Stecca, B. A. (2018) · Cells · doi:10.3390/cells7120272 · Cited by 46
“Other oncogenic mutations of SMO that are associated with constitutive HH pathway activation include: L412F, which has been reported in desmoplastic MB [88], meningiomas [82], and ameloblastomas, where it has been associated with insensitivity to vismodegib [81]; S533N in primitive neuroectodermal tumors (PNET) [83];…”
BackgroundRadiotherapy Advances in Paediatric Medulloblastoma Treatment
Padovani, L., Horan, G., & Ajithkumar, T. (2019) · Clinical Oncology · doi:10.1016/j.clon.2019.01.001 · Cited by 53
Zhang, H., Zhu, D., Zhang, Z., Kaluz, Š., Yu, B., Devi, N. S., Olson, J. J., & Meir, E. G. V. (2019) · Oncogene · doi:10.1038/s41388-019-1036-7 · Cited by 48
Korshunov, A., Chávez, L., Northcott, P. A., Sharma, T. S., Ryzhova, M. V., Jones, D., von Deimling, A., Pfister, S. M., & Kool, M. (2017) · Acta Neuropathologica · doi:10.1007/s00401-017-1776-9 · Cited by 49
“These discordant cases were confirmed to be non-SHHMBs based on the presence of isochromosome 17 in all of them [3, 4].”
BackgroundResultSelf-citationLi, D., Lei, S., Wang, Y.-Y., Chen, S., Kang, Y., Gu, Z., & Zhang, J. (2018) · Dalton Transactions · doi:10.1039/c8dt00761f · Cited by 44
Self-citationEmbryonal Tumors of the Central Nervous System in Children: The Era of Targeted Therapeutics
Kram, D. E., Henderson, J. J., Baig, M., Chakraborty, D., Gardner, M. A., Biswas, S., & Khatua, S. (2018) · Bioengineering · doi:10.3390/bioengineering5040078 · Cited by 50
“MB subgroups exhibit distinct biological characteristics, and recent application of advanced algorithms for integrative genomic analysis has highlighted heterogeneity even within these subgroups, which may help inform patient stratification in future trials (Figure 1) [16].”
BackgroundFinlay, J. B., Ireland, A. S., Hawgood, S. B., Reyes, T., Ko, T., Olsen, R. R., Hachem, R. A., Jang, D. W., Bell, D., Chan, J. M., et al. (2024) · Cancer Cell · doi:10.1016/j.ccell.2024.05.003 · Cited by 46
Blaeschke, F., Paul, M. C., Schuhmann, M. U., Rabsteyn, A., Schroeder, C., Casadei, N., Matthes, J., Mohr, C., Lotfi, R., Wagner, B., et al. (2019) · Cytotherapy · doi:10.1016/j.jcyt.2019.06.009 · Cited by 44
Self-citationThe Power of Human Cancer Genetics as Revealed by Low-Grade Gliomas
Jones, D., Bandopadhayay, P., & Jabado, N. (2019) · Annual Review of Genetics · doi:10.1146/annurev-genet-120417-031642 · Cited by 51
Self-citationRausch, T., Snajder, R., Léger, A., Simovic-Lorenz, M., Giurgiu, M., Villacorta, L., Henssen, A. G., Fröhling, S., Stegle, O., Birney, E., et al. (2023) · Cell Genomics · doi:10.1016/j.xgen.2023.100281 · Cited by 45
Self-citationAn OTX2-PAX3 signaling axis regulates Group 3 medulloblastoma cell fate
Zagozewski, J. L., Shahriary, G. M., Morrison, L. C., Saulnier, O., Stromecki, M., Fresnoza, A. L., Palidwor, G., Porter, C. J., Forget, A., Ayrault, O., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-17357-4 · Cited by 52
Self-citationTemporal patterning in neural progenitors: from Drosophila development to childhood cancers
Maurange, C. (2020) · Disease Models & Mechanisms · doi:10.1242/dmm.044883 · Cited by 45
Neurotrophin Signaling in Medulloblastoma
Thomaz, A., Jaeger, M. D. C., Brunetto, A. L., Brunetto, A. T., Gregianin, L. J., de Farias, C. B., Ramaswamy, V., Nör, C., Taylor, M. D., & Roesler, R. (2020) · Cancers · doi:10.3390/cancers12092542 · Cited by 46
“Expression levels were examined in previously described transcriptome data sets comprising samples from Pfister (n = 223 MB samples; [22]), Roth (n = 9 normal cerebellum samples; [11]), and Cavalli et al.”
BackgroundSelf-citationEffective inhibition of MYC-amplified group 3 medulloblastoma by FACT-targeted curaxin drug CBL0137
Wang, J., Sui, Y., Li, Q., Zhao, Y., Dong, X., Yang, J., Liang, Z., Han, Y., Tang, Y., & Ma, J. (2020) · Cell Death and Disease · doi:10.1038/s41419-020-03201-6 · Cited by 40
Targeting MYCN in Molecularly Defined Malignant Brain Tumors
Borgenvik, A., Čančer, M., Hutter, S., & Swartling, F. J. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2020.626751 · Cited by 45
Chen, Z., Ioris, R. M., Richardson, S., Van Ess, A. N., Vendrell, I., Kessler, B. M., Buffa, F. M., Busino, L., Clifford, S. C., Bullock, A. N., et al. (2022) · Cell Death & Differentiation · doi:10.1038/s41418-022-00983-4 · Cited by 41
“1A) [5] from HEK293T cells and performed tryptic digestion and Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS) to analyse their interacting partners.”
BackgroundMethodInfluentialPrinciples of tumorigenesis and emerging molecular drivers of SHH ‐activated medulloblastomas
Menyhárt, O., & Győrffy, B. (2019) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.762 · Cited by 49
“KMT2D and KMT2C methyltransferase mutations occur with relatively high frequency within both pediatric and adult samples.(22) Mutations deregulating histone-acetyltransferase (HAT) complexes involving genes such as CREBBP, KAT6B, EP300, BRPF1, and KANSL1 are present in approximately 19% of all SHHMB patients.”
BackgroundInfluentialNazio, F., Pò, A., Abballe, L., Ballabio, C., Diomedi‐Camassei, F., Bordi, M., Camera, A., Caruso, S., Caruana, I., Pezzullo, M., et al. (2021) · Acta Neuropathologica · doi:10.1007/s00401-021-02347-7 · Cited by 48
“Using genome-wide DNA methylation and gene expression analyses, 12 different subtypes of MB have been recognized, highlighting the heterogeneous and complex nature of disease subgroups [13, 64].”
BackgroundResultRay, S., Chaturvedi, N. K., Bhakat, K. K., Rizzino, A., & Mahapatra, S. (2021) · Diagnostics · doi:10.3390/diagnostics12010061 · Cited by 57
“Multiple studies, including several recent large-scale studies, have demonstrated that survival of all MB patients, including those with SHH MB, are highly dependent on the molecular characteristics of the tumor [22,62,63].”
BackgroundResultInfluentialIncorporating Advances in Molecular Pathology Into Brain Tumor Diagnostics
Vega, J. E. V., & Brat, D. J. (2018) · Advances in Anatomic Pathology · doi:10.1097/pap.0000000000000186 · Cited by 40
Frappaz, D., Barritault, M., Montané, L., Laigle–Donadey, F., Chinot, O. L., Rhun, É. L., Bonneville-Levard, A., Hottinger, A. F., Meyronnet, D., Bidaux, A.-S., et al. (2021) · Neuro-Oncology · doi:10.1093/neuonc/noab087 · Cited by 41
Zhao, L., Wang, W., Xu, L., Yi, T., Zhao, X., Wei, Y., Vermeulen, L., Goel, A., Zhou, S., & Wang, X. (2019) · Oncogene · doi:10.1038/s41388-019-0896-1 · Cited by 44
Isocitrate dehydrogenase 1 primes group-3 medulloblastomas for cuproptosis
Dang, D., Deogharkar, A., McKolay, J., Smith, K. S., Panwalkar, P., HOFFMAN, S. S., Tian, W., Ji, S., Azambujá, A. P., Natarajan, S. K., et al. (2025) · Cancer Cell · doi:10.1016/j.ccell.2025.04.013 · Cited by 44
Self-citationYi, J., Shi, X., Xuan, Z., & Wu, J. I. (2020) · Cancer Letters · doi:10.1016/j.canlet.2020.11.031 · Cited by 37
“In human SHH medulloblastoma patients, UTX mutations were identified, albeit with low frequencies (52).”
BackgroundHuman Medulloblastoma Cell Lines: Investigating on Cancer Stem Cell-Like Phenotype
Casciati, A., Tanori, M., Manczak, R., Saada, S., Tanno, B., Giardullo, P., Porcù, E., Rampazzo, E., Persano, L., Viola, G., et al. (2020) · Cancers · doi:10.3390/cancers12010226 · Cited by 41
Visvanathan, A., Saulnier, O., Chen, C., Haldipur, P., Orisme, W., Delaidelli, A., Shin, S., Millman, J., Bryant, A., Abeysundara, N., et al. (2024) · Cell · doi:10.1016/j.cell.2024.06.011 · Cited by 41
Self-citationThe long noncoding RNA lnc-HLX-2-7 is oncogenic in Group 3 medulloblastomas
Katsushima, K., Lee, B., Kunhiraman, H., Zhong, C., Murad, R., Yin, J., Liu, B., Garancher, A., González-Gómez, I., Monforte, H. L., et al. (2020) · Neuro-Oncology · doi:10.1093/neuonc/noaa235 · Cited by 50
Primary cilia control translation and the cell cycle in medulloblastoma
Youn, Y. H., Hou, S., Wu, C., Kawauchi, D., Orr, B. A., Robinson, G. W., Finkelstein, D., Taketo, M. M., Gilbertson, R. J., Roussel, M. F., et al. (2022) · Genes & Development · doi:10.1101/gad.349596.122 · Cited by 37
Self-citationSchwalbe, E. C., Lindsey, J. C., Danilenko, M., Hill, R. M., Crosier, S., Ryan, S. L., Williamson, D., Castle, J., Hicks, D., Kool, M., et al. (2024) · Neuro-Oncology · doi:10.1093/neuonc/noae178 · Cited by 41
“…significance to MYC(N)- amplified tumors; these include the identification of component molecular subgroups within each molecular group 17,23–25 which are detected using DNA methylation microarray, alongside variations in the pattern and proportion of cells displaying MYC(N) amplification.”
Self-citationMedulloblastoma in the Molecular Era
Kuzan-Fischer, C. M., Juraschka, K., & Taylor, M. D. (2018) · Journal of Korean Neurosurgical Society · doi:10.3340/jkns.2018.0028 · Cited by 45
Self-citationMouse medulloblastoma driven by CRISPR activation of cellular Myc
Vo, B. T., Kwon, J. A., Li, C., Finkelstein, D., Xu, B., Orr, B. A., Sherr, C. J., & Roussel, M. F. (2018) · Scientific Reports · doi:10.1038/s41598-018-24956-1 · Cited by 39
Self-citationModeling SHH-driven medulloblastoma with patient iPS cell-derived neural stem cells
Susanto, E., Navarro, A. M., Zhou, L., Sundström, A., van Bree, N. F. H. N., Stantic, M., Moslem, M., Tailor, J. K., Rietdijk, J., Zubillaga, V., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1920521117 · Cited by 35
“Next, we examined array data from human medulloblastoma patients (27, 35 – 37) to investigate LGALS1 expression levels in different subgroups of human medulloblastoma (Fig.”
Self-citationExploration of Coding and Non-coding Variants in Cancer Using GenomePaint
Zhou, X., Wang, J., Patel, J. N., Valentine, M. B., Shao, Y., Newman, S., Sioson, E., Tian, L., Liu, Y., Brady, S. W., et al. (2021) · Cancer Cell · doi:10.1016/j.ccell.2020.12.011 · Cited by 35
Self-citationZou, H., Poore, B., Brown, E. E., Qian, J., Xie, B., Asimakidou, E., Razskazovskiy, V., Ayrapetian, D., Sharma, V., Xia, S., et al. (2023) · Nature Cell Biology · doi:10.1038/s41556-023-01093-0 · Cited by 38
Self-citationDevelopmental origins shape the paediatric cancer genome
Chen, X., Yang, W., Roberts, C. W. M., & Zhang, J. (2024) · Nature reviews. Cancer · doi:10.1038/s41568-024-00684-9 · Cited by 56
Self-citationRodriguez-Blanco, J., Li, B., Long, J., Shen, C., Yang, F., Orton, D., Collins, S., Kasahara, N., Ayad, N. G., McCrea, H. J., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1319 · Cited by 34
Kallay, L. M., Keskin, H., Ross, A., Rupji, M., Moody, O. A., Wang, X., Li, G., Ahmed, T., Rashid, F., Stephen, M. R., et al. (2019) · Journal of Neuro-Oncology · doi:10.1007/s11060-019-03115-0 · Cited by 39
Self-citationScicchitano, S., Giordano, M., Lucchino, V., Montalcini, Y., Chiarella, E., Aloisio, A., Codispoti, B., Zoppoli, P., Melocchi, V., Bianchi, F., et al. (2019) · Cell Death and Disease · doi:10.1038/s41419-019-1946-x · Cited by 37
Role of protein arginine methyltransferase 5 in group 3 (MYC-driven) Medulloblastoma
Chaturvedi, N. K., Mahapatra, S., Kesherwani, V., Kling, M. J., Shukla, M., Ray, S., Kanchan, R. K., Perumal, N., McGuire, T. R., Sharp, J. G., et al. (2019) · BMC Cancer · doi:10.1186/s12885-019-6291-z · Cited by 40
Splicing Dysregulation as Oncogenic Driver and Passenger Factor in Brain Tumors
Bielli, P., Pagliarini, V., Pieraccioli, M., Caggiano, C., & Sette, C. (2019) · Cells · doi:10.3390/cells9010010 · Cited by 36
“Among them, WNT MB displays the most favorable prognosis, whereas Group 3 shows the worst prognosis, and SHH and Group 4 MBs are characterized by an intermediated clinical course [13,14].”
BackgroundIntratumoral heterogeneity of MYC drives medulloblastoma metastasis and angiogenesis
Qin, N., Paisana, E., Langini, M., Picard, D. J., Malzkorn, B., Custódia, C., Cascão, R., Meyer, F.-D., Blümel, L., Göbbels, S., et al. (2022) · Neuro-Oncology · doi:10.1093/neuonc/noac068 · Cited by 36
Bartl, J., Zanini, M., Bernardi, F., Forget, A., Blümel, L., Talbot, J., Picard, D. J., Qin, N., Cancila, G., Gao, Q., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-31574-z · Cited by 34
Self-citationKutscher, L. M., Okonechnikov, K., Batora, N. V., Clark, J., Silva, P. B. G., Vouri, M., van Rijn, S., Sieber, L., Statz, B., Gearhart, M. D., et al. (2020) · Genes & Development · doi:10.1101/gad.337584.120 · Cited by 36
“The presence of BCORmutations and indels was integrated from our previous medulloblastoma studies (Kool et al. 2014; Northcott et al. 2017; Waszak et al. 2020).”
BackgroundInfluentialSelf-citationBiological and clinical implications of FGFR aberrations in paediatric and young adult cancers
Brown, L. M., Ekert, P. G., & Fleuren, E. D. G. (2023) · Oncogene · doi:10.1038/s41388-023-02705-7 · Cited by 42
“In paediatric brain tumours, elevated expression of FGFRs have been reported in medulloblastoma and ependymoma, two common paediatric brain tumours in which genomic aberration of FGFRs is not a characteristic [11, 94].”
BackgroundPenas, C., Maloof, M. E., Stathias, V., Long, J., Tan, S. K., Mier, J., Fang, Y., Valdes, C., Rodríguez‐Blanco, J., Chiang, C., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-10799-5 · Cited by 35
Methylation‐based algorithms for diagnosis: experience from neuro‐oncology
Pickles, J. C., Stone, T. J., & Jacques, T. S. (2020) · The Journal of Pathology · doi:10.1002/path.5397 · Cited by 38
“However, recent studies analysing larger tumour cohorts indicate much greater molecular granularity across Groups 3 and 4 [20,23-25], and a consensus of 8 separate groups has been reached; associated with different clinical outcomes [20] (Figure 1A).”
BackgroundZou, H., Poore, B., Broniscer, A., Pollack, I. F., & Hu, B. (2020) · Cancers · doi:10.3390/cancers12030643 · Cited by 39
“To this end, Shih et al. identified a small panel of cytogenetic biomarkers (GLI2, MYC, chr11, chr14, 17p, and 17q) to distinguish high-risk and low-risk patients with SHH, Group 3, and Group 4 MBs, which may provide an excellent tool in patient selection for precision therapy [73].”
BackgroundInfluentialTargeting fibroblast growth factor receptors to combat aggressive ependymoma
Lötsch, D., Kirchhofer, D., Englinger, B., Jiang, L., Okonechnikov, K., Senfter, D., Laemmerer, A., Gabler, L., Pirker, C., Donson, A. M., et al. (2021) · Acta Neuropathologica · doi:10.1007/s00401-021-02327-x · Cited by 34
“The Heidelberg dataset comprised mRNA expression profiles analyzed by u133 Affymetrix gene expression array (n = 356 EPN, n = 657 MB, n = 539 pediatric glioblastoma multiforme/ GBM, n = 506 others) and RNA sequencing (n = 25 EPN, n = 167 MB, n = 30 GBM) from corresponding studies [8, 35, 43].”
Self-citationRecent advances in the molecular understanding of medulloblastoma
Funakoshi, Y., Sugihara, Y., Uneda, A., Nakashima, T., & Suzuki, H. (2022) · Cancer Science · doi:10.1111/cas.15691 · Cited by 44
Preferential sensitivity to HDAC inhibitors in tumors with CREBBP mutation
Hellwig, M., Merk, D. J., Lutz, B., & Schüller, U. (2019) · Cancer Gene Therapy · doi:10.1038/s41417-019-0099-5 · Cited by 32
van Bree, N. F. H. N., & Wilhelm, M. (2022) · Cancers · doi:10.3390/cancers14205009 · Cited by 36
“Other aberrations enriched in childhood and adult SHH-MB are mutations in TP53 and the TERT promoter, respectively (Figure 2) [51,53].”
BackgroundStitzlein, L. M., Adams, J. T., Stitzlein, E., Dudley, R. W., & Chandra, J. (2024) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-023-02923-7 · Cited by 35
van Essen, M. J., Apsley, E. J., Riepsaame, J., Xu, R., Northcott, P. A., Cowley, S. A., Jacob, J., & Becker, E. B. E. (2024) · Disease Models & Mechanisms · doi:10.1242/dmm.050323 · Cited by 35
Self-citationMultisite dependency of an E3 ligase controls monoubiquitylation-dependent cell fate decisions
Werner, A. A., Baur, R., Teerikorpi, N., Kaya, D. U., & Rapé, M. (2018) · eLife · doi:10.7554/elife.35407 · Cited by 35
Immunotherapy in Medulloblastoma: Current State of Research, Challenges, and Future Perspectives
Voskamp, M. J., Li, S., van Daalen, K. R., Crnko, S., ten Broeke, T., & Bovenschen, N. (2021) · Cancers · doi:10.3390/cancers13215387 · Cited by 39
“The majority of WNT tumors are the result of a somatic activating mutation of catenin beta 1 (CTNNB1), leading to a consistent activation of β-catenin and constitutive WNT pathway signaling [4,24].”
BackgroundInfluentialDiagnostic Yield From a Nationwide Implementation of Precision Medicine for all Children With Cancer
Wadensten, E., Wessman, S., Abel, F., de Ståhl, T. D., Tesi, B., Orsmark‐Pietras, C., Arvidsson, L., Taylan, F., Fransson, S. M., Vogt, H., et al. (2023) · JCO Precision Oncology · doi:10.1200/po.23.00039 · Cited by 39
“5,6,23,24 In speci fi c cases, all nonsynonymous exonic somatic variants were also reviewed manually.”
BackgroundSomatic structural variant formation is guided by and influences genome architecture
Sidiropoulos, N., Mardin, B. R., Rodríguez-González, F. G., Bochkov, I. D., Garg, S., Stütz, A. M., Korbel, J. O., Aiden, E. L., & Weischenfeldt, J. (2022) · Genome Research · doi:10.1101/gr.275790.121 · Cited by 34
“Moreover, SVs can alter the 3D organization, which can havedirect consequencesongene regulation(Lupiáñezet al.2015; Northcott et al. 2017; Weischenfeldt et al. 2017; Dixon et al. 2018; Akdemir et al. 2020).”
BackgroundSelf-citationLi, Y., Yu, Z., Jiang, T., Shao, L., Liu, Y., Li, N., Wu, Y., Zheng, C., Wu, X., Zhang, M., et al. (2018) · Cancer Science · doi:10.1111/cas.13515 · Cited by 31
“Recently, each subgroup of MB was split further based on comprehensive molecular profiling that can improve disease risk stratification and inform treatment decisions.(42,43) In order to integrate more diagnostic markers and candidates for therapeutic targets of this tumor into one testing platform, we also investigat…”
BackgroundSelf-citationCurran, T. (2018) · Open Biology · doi:10.1098/rsob.180098 · Cited by 28
Genetic Abnormalities, Clonal Evolution, and Cancer Stem Cells of Brain Tumors
Testa, U., Castelli, G., & Pelosi, E. (2018) · Medical Sciences · doi:10.3390/medsci6040085 · Cited by 44
“Particularly, 100% of medulloblastoma samples pertaining to the WNT subgroup were assigned to at least one driver gene: somatic CTNNB1 mutations were observed in 86% of these patients (three patients with CTNNB1 wild-type harbored pathogenic APC germline variants) and monosomy, a chromosome abnormality typical of thes…”
BackgroundInfluentialBharambe, H. S., Paul, R., Panwalkar, P., Jalali, R., Epari, S., Gupta, T., Moiyadi, A. V., Shetty, P. M., Kazi, S., Deogharkar, A., et al. (2019) · Acta Neuropathologica Communications · doi:10.1186/s40478-019-0697-3 · Cited by 34
“Highly integrative analysis that integrated somatic mutation data analysis in addition to the genome wide methylation, transcriptome and copy number variation data has reported 8 subtypes within the Group 3/Group 4 medulloblastomas [34].”
BackgroundSelf-citationThe Emerging Role of Ras Pathway Signaling in Pediatric Cancer
Ney, G. M., McKay, L. M., Koschmann, C. J., Mody, R. J., & Li, Q. (2020) · Cancer Research · doi:10.1158/0008-5472.can-20-0916 · Cited by 36
Safaei, S., Mohme, M., Niesen, J., Schüller, U., & Bockmayr, M. L. (2021) · OncoImmunology · doi:10.1080/2162402x.2021.1932365 · Cited by 31
Recent Advances in Pediatric Cancer Research
McEachron, T. A., & Helman, L. J. (2021) · Cancer Research · doi:10.1158/0008-5472.can-21-1191 · Cited by 40
“DNAmethylation arrays subdivided group 3 and 4 medulloblastomas into 8 different molecular subgroups (10).”
BackgroundLiang, B., Zhou, Y., Jiao, J., Xu, L., Yan, Y., Wu, Q., Tong, X., & Yan, H. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.875521 · Cited by 34
“CTNNB1 mutations, for example, are a particular manifestation of the WNT molecular subtype and have diagnostic relevance (5, 6).”
BackgroundAdvances in the Treatment of Pediatric Brain Tumors
Kulubya, E. S., Kercher, M. J., Phillips, H. W., Antony, R., & Edwards, M. S. B. (2022) · Children · doi:10.3390/children10010062 · Cited by 40
“TERT promoter mutations are also present in 40% of SHH medulloblastomas and in most adult cases [49].”
BackgroundCambruzzi, E. (2018) · Child s Nervous System · doi:10.1007/s00381-018-3765-2 · Cited by 36
Hijacked enhancer–promoter and silencer–promoter loops in cancer
Wang, X., & Yue, F. (2024) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2024.102199 · Cited by 33
New Approaches in Targeted Therapy for Medulloblastoma in Children
MAIER, H., Dalianis, T., & Kostopoulou, O. N. (2021) · Anticancer Research · doi:10.21873/anticanres.14936 · Cited by 34
Polycomb repressive complex 2 in the driver’s seat of childhood and young adult brain tumours
Krug, B., Harutyunyan, A. S., Deshmukh, S., & Jabado, N. (2021) · Trends in Cell Biology · doi:10.1016/j.tcb.2021.05.006 · Cited by 30
Self-citationThe epidemiology of primary and metastatic brain tumors in infancy through childhood
Lamba, N., Groves, A. P., Torre, M., Yeo, K. K., & Iorgulescu, J. B. (2022) · Journal of Neuro-Oncology · doi:10.1007/s11060-021-03927-z · Cited by 29
Sanjaya, P., Maljanen, K., Katainen, R., Waszak, S. M., Ambrose, J. C., Arumugam, P., Bevers, R. P. J., Bleda, M., Boardman-Pretty, F., Boustred, C., et al. (2023) · Genome Medicine · doi:10.1186/s13073-023-01204-4 · Cited by 35
“One of these was found to correspond to the Sonic Hedgehog (SHH)-activated medulloblastomas of adult patients with mutation landscapes dominated by the age-associated CpG>TpG substitutions [49].”
BackgroundSelf-citationBagchi, A., Dhanda, S. K., Dunphy, P., Sioson, E., & Robinson, G. W. (2023) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2023.7024 · Cited by 28
“One of the first studies to show this applied t-distributed stochastic neighbor embedding (t-SNE) to 740 G3/G4 medulloblastoma samples profiled by DNA methylation and found 8 methylation subgroups (I–VIII).(42) Of these, subgroup IV is the most prevalent in infants ( 60%), and only small numbers from I, II, III, VII,…”
BackgroundSelf-citationPediatric Central Nervous System Tumor Overview and Emerging Treatment Considerations
Damodharan, S. N., & Puccetti, D. (2023) · Brain Sciences · doi:10.3390/brainsci13071106 · Cited by 36
“(I–VIII) with their key molecular abnormalities listed within the figure [83,84].”
BackgroundHeterogeneity and tumoral origin of medulloblastoma in the single-cell era
Sheng, H., Li, H., Zeng, H., Zhang, B., Yu, L., Liu, X., Xu, Z., Zhang, J., & Zhang, L. (2024) · Oncogene · doi:10.1038/s41388-024-02967-9 · Cited by 35
“Other frequently mutated genes are DDX3X , SMARCA4 , CREBBP and KMT2D , which encode proteins that can interact with β -catenin [9, 45].”
BackgroundSelf-citationCharacterization of a novel OTX 2‐driven stem cell program in Group 3 and Group 4 medulloblastoma
Stromecki, M., Tatari, N., Morrison, L. C., Kaur, R., Zagozewski, J. L., Palidwor, G., Ramaswamy, V., Skowron, P., Wölfl, M., Milde, T., et al. (2018) · Molecular Oncology · doi:10.1002/1878-0261.12177 · Cited by 37
“Indeed, recent studies have identified up to 12 MB subtypes within the subgroups that display unique genetic, epigenetic and molecular signatures (Cavalli et al., 2017; Northcott et al., 2017; Schwalbe et al., 2017).”
BackgroundSelf-citationPVT1: A long non-coding RNA recurrently involved in neoplasia-associated fusion transcripts
Tolomeo, D., Agostini, A., Visci, G., Traversa, D., & Storlazzi, C. T. (2021) · Gene · doi:10.1016/j.gene.2021.145497 · Cited by 27
Hamdan, A., & Ewing, A. (2022) · The Journal of Pathology · doi:10.1002/path.5901 · Cited by 34
“For example, in medulloblastoma, different SV classes juxtapose the proto-oncogenes GFI1 and GFI1B to distal active enhancer elements [140], increasing their expression.”
BackgroundGenetic alterations of TP53 and OTX2 indicate increased risk of relapse in WNT medulloblastomas
Goschzik, T., Mynarek, M., Doerner, E., Schenk, A., Spier, I., Warmuth‐Metz, M., Bison, B., Obrecht, D., Struve, N., Kortmann, R., et al. (2022) · Acta Neuropathologica · doi:10.1007/s00401-022-02505-5 · Cited by 29
Zhang, H., Zhu, D., Zhang, Z., Kaluz, Š., Yu, B., Devi, N. S., Olson, J. J., & Meir, E. G. V. (2019) · Oncogene · doi:10.1038/s41388-019-1067-0 · Cited by 28
Tamayo-Orrego, L., Gallo, D., Racicot, F., Bemmo, A., Mohan, S., Ho, B., Salameh, S., Hoang, T., Jackson, A. P., Brown, G. W., et al. (2020) · Nature Cancer · doi:10.1038/s43018-020-0094-7 · Cited by 28
Lorenz, J., Rothhammer-Hampl, T., Zoubaa, S., Bumes, E., Pukrop, T., Kölbl, O., Corbacioglu, S., Schmidt, N. O., Proescholdt, M. A., Hau, P., et al. (2020) · Acta Neuropathologica Communications · doi:10.1186/s40478-020-01000-w · Cited by 32
Hicks, D., Rafiee, G., Schwalbe, E. C., Howell, C. I., Lindsey, J. C., Hill, R. M., Smith, A. J., Adidharma, P., Steel, C., Richardson, S., et al. (2020) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.12656 · Cited by 28
Epigenetic pathways and plasticity in brain tumors
Suter, R. K., Rodríguez‐Blanco, J., & Ayad, N. G. (2020) · Neurobiology of Disease · doi:10.1016/j.nbd.2020.105060 · Cited by 30
Liu, A. P. Y., Northcott, P. A., Robinson, G. W., & Gajjar, A. J. (2021) · Laboratory Investigation · doi:10.1038/s41374-021-00719-x · Cited by 30
Self-citationDynamic Interplay between Structural Variations and 3D Genome Organization in Pancreatic Cancer
Du, Y., Gu, Z., Li, Z., Yuan, Z., Zhao, Y., Zheng, X., Bo, X., Chen, H., & Wang, C. (2022) · Advanced Science · doi:10.1002/advs.202200818 · Cited by 31
Self-citationDormant SOX9-Positive Cells Facilitate MYC-Driven Recurrence of Medulloblastoma
Borgenvik, A., Holmberg, K. O., Bolin, S., Zhao, M., Savov, V., Rosén, G., Hutter, S., Garancher, A., Rahmanto, A. S., Bergström, T., et al. (2022) · Cancer Research · doi:10.1158/0008-5472.can-22-2108 · Cited by 30
Self-citationLuo, Z., Liao, Y., Xin, D., Berry, K., Ogurek, S., Dong, X., Li, H., Yu, J., Zhang, F., Han, R., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-36400-8 · Cited by 30
“Chr: ~ 70 Chr: ~ 57 Chr: ~ 40 Myc(4+)/Chr15(4) Myc(2)/Chr15(2) Myc(6+)/Chr15(6) Ctrl NPC cKO NPC cKO tumor cell cKO_shCtrl cKO_shMyc-1 cKO_shMyc-2”
Self-citationMa, P., An, T., Zhu, L., Zhang, L., Wang, H., Ren, B., Sun, B., Zhou, X., Li, Y., & Mao, B. (2020) · Development · doi:10.1242/dev.188078 · Cited by 26
Self-citationTang, L., Wang, M., Shen, C., Wen, L., Li, M., Wang, D., Zheng, X., Sheng, Y., Wu, W., Zhang, C., et al. (2021) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2020.12.031 · Cited by 27
Vellichirammal, N. N., Chaturvedi, N. K., Joshi, S. S., Coulter, D. W., & Guda, C. (2020) · Cancer Letters · doi:10.1016/j.canlet.2020.11.015 · Cited by 26
Metadata
- Authors
- Northcott, P. A., Buchhalter, I., Morrissy, A. S., Hovestadt, V., Weischenfeldt, J., Ehrenberger, T., Gröbner, S., Segura-Wang, M., Zichner, T., Rudneva, V. A., Warnatz, H.-J., Sidiropoulos, N., Phillips, A. H., Schumacher, S., Kleinheinz, K., Waszak, S. M., Erkek, S., Jones, D. T. W., Worst, B. C., Kool, M., Zapatka, M., Jäger, N., Chavez, L., Hutter, B., Bieg, M., Paramasivam, N., Heinold, M., Gu, Z., Ishaque, N., Jäger-Schmidt, C., Imbusch, C. D., Jugold, A., Hübschmann, D., Risch, T., Amstislavskiy, V., Gonzalez, F. G. R., Weber, U. D., Wolf, S., Robinson, G. W., Zhou, X., Wu, G., Finkelstein, D., Liu, Y., Cavalli, F. M. G., Luu, B., Ramaswamy, V., Wu, X., Koster, J., Ryzhova, M., Cho, Y.-J., Pomeroy, S. L., Herold-Mende, C., Schuhmann, M., Ebinger, M., Liau, L. M., Mora, J., McLendon, R. E., Jabado, N., Kumabe, T., Chuah, E., Ma, Y., Moore, R. A., Mungall, A. J., Mungall, K. L., Thiessen, N., Tse, K., Wong, T., Jones, S. J. M., Witt, O., Milde, T., Von Deimling, A., Capper, D., Korshunov, A., Yaspo, M.-L., Kriwacki, R., Gajjar, A., Zhang, J., Beroukhim, R., Fraenkel, E., Korbel, J. O., Brors, B., Schlesner, M., Eils, R., Marra, M. A., Pfister, S. M., Taylor, M. D., & Lichter, P.
- Affiliations
- St. Jude Children's Research Hospital (US)
- German Cancer Research Center (DE)
- Hospital for Sick Children (CA)
- University of Copenhagen (DK)
- Massachusetts Institute of Technology (US)
- European Molecular Biology Laboratory (DE)
- Max Planck Institute for Molecular Genetics (DE)
- Broad Institute (US)
- Burdenko Neurosurgery Institute (RU)
- Oregon Health & Science University (US)
- Boston Children's Hospital (US)
- Universitätsklinikum Tübingen (DE)
- University Children's Hospital Tübingen (DE)
- University of California, Los Angeles (US)
- Hospital Sant Joan de Déu Barcelona (ES)
- Duke University (US)
- McGill University (CA)
- Kitasato University Hospital (JP)
- BC Cancer Agency (CA)
- University Hospital Heidelberg (DE)
- Corresponding author
- Pfister, Stefan M.
- Taylor, Michael D.
- Lichter, Peter
- ORCID
- Northcott, Paul A.
- Buchhalter, Ivo
- Morrissy, A. Sorana
- Hovestadt, Volker
- Weischenfeldt, Joachim
- Zichner, Thomas
- Rudneva, Vasilisa A.
- Warnatz, Hans-Jörg
- Sidiropoulos, Nikos
- Phillips, Aaron H.
- Schumacher, Steven
- Kleinheinz, Kortine
- Waszak, Sebastian M.
- Erkek, Serap
- Jones, David T. W.
- Kool, Marcel
- Zapatka, Marc
- Jäger, Natalie
- Hutter, Barbara
- Bieg, Matthias
- Paramasivam, Nagarajan
- Gu, Zuguang
- Ishaque, Naveed
- Imbusch, Charles D.
- Hübschmann, Daniel
- Amstislavskiy, Vyacheslav
- Robinson, Giles W.
- Zhou, Xin
- Wu, Gang
- Finkelstein, David
- Liu, Yanling
- Cavalli, Florence M. G.
- Ramaswamy, Vijay
- Wu, Xiaochong
- Ryzhova, Marina
- Cho, Yoon-Jae
- Pomeroy, Scott L.
- Schuhmann, Martin
- Ebinger, Martin
- Liau, Linda M.
- Mora, Jaume
- McLendon, Roger E.
- Jabado, Nada
- Kumabe, Toshihiro
- Moore, Richard A.
- Mungall, Andrew J.
- Wong, Tina
- Jones, Steven J. M.
- Witt, Olaf
- Milde, Till
- Capper, David
- Korshunov, Andrey
- Yaspo, Marie-Laure
- Kriwacki, Richard
- Gajjar, Amar
- Zhang, Jinghui
- Beroukhim, Rameen
- Fraenkel, Ernest
- Korbel, Jan O.
- Brors, Benedikt
- Schlesner, Matthias
- Eils, Roland
- Marra, Marco A.
- Pfister, Stefan M.
- Taylor, Michael D.
- Lichter, Peter
- Venue
- Nature
- Published
- 2017-07
- Volume
- 547
- Issue
- 7663
- Pages
- 311-317
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC5905700
- OpenAlex
- W2737542366
- Cited by
- 1,112
- References
- 66
- Citations by year
- 2026: 63 · 2025: 132 · 2024: 125 · 2023: 154 · 2022: 142 · 2021: 148 · 2020: 120 · 2019: 120 · 2018: 94 · 2017: 12
- FWCI
- 54.51
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor, 19 d)
- Locations
- Nature (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion, cc-by)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- DSpace@MIT (Massachusetts Institute of Technology) (submittedVersion, cc-by)
- eScholarship (California Digital Library) (submittedVersion)
- eScholarship (California Digital Library) (submittedVersion, cc-by)
- Max Planck Digital Library (submittedVersion, other-oa)
- Pure Amsterdam UMC (submittedVersion, other-oa)
- MPG.PuRe (Max Planck Society) (submittedVersion, cc-by)
- OPUS (Augsburg University) (submittedVersion, cc-by)
- Funders
- Alexander and Margaret Stewart Trust
- Pediatric Brain Tumor Foundation (R01CA159859)
- Deutsches Krebsforschungszentrum
- Genome Canada (R01CA159859)
- Children's Hospital Foundation
- Ontario Institute for Cancer Research
- American Lebanese Syrian Associated Charities
- Government of Ontario
- Genome British Columbia (R01CA159859)
- Canada Research Chairs
- Brain Tumour Charity (GN-000356)
- Bundesministerium für Bildung und Forschung (01KU1505E, 01KU1201A, 01KU1505A)
- Terry Fox Research Institute (R01CA159859)
- Deutsche Krebshilfe (109252)
- Hospital for Sick Children
- Stichting Kinderen Kankervrij
- BC Cancer Foundation (FDN-143288)
- Brain Tumour Research
- National Institutes of Health
- Heidelberger Zentrum für Personalisierte Onkologie Deutsches Krebsforschungszentrum In Der Helmholtz-Gemeinschaft
- Garron Family Cancer Centre
- National Cancer Institute (R01CA148699, R01CA109467, R01CA159859)
- Topics
- Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Keywords
- medulloblastoma, molecular subtypes, driver mutations, somatic mutations, mutational signatures, enhancer hijacking, in-frame insertion, DNA methylation, Group 3 medulloblastoma, Group 4 medulloblastoma, therapeutic target, childhood brain tumours, integrative genomics
- MeSH terms
- Whole Genome Sequencing, Carrier Proteins, DNA Mutational Analysis, Epistasis, Genetic, Humans, Medulloblastoma, Muscle Proteins, Mutation, Oncogenes, Transcription Factors, Cohort Studies, Genome, Human, DNA Methylation, Genomics, Wnt Proteins, Molecular Targeted Therapy, Carcinogenesis, Datasets as Topic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.